Clinical trials: Controlled Hypertension
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension
Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of adult patients with diagnosis of arterial…
- Trial name
- NCT01850160
- Testing
- GROUP A: Valsartan plus Chlorthalidone, GROUP B: Valsartan, GROUP C: Chlorthalidone
- Where
- 8 sites in Colombia, Ecuador
- Volunteers
- 124 people
- Sponsor
- Farma de Colombia SA
Hypertension
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
The purpose of this study is to gain an understanding of the actual use of candesartan cilexetil (Blopress) in patients with hypertension, and to examine the changes in parameters such as blood pressure.
- Trial name
- NCT02211638
- Testing
- Candesartan Cilexetil
- Where
- Japan
- Volunteers
- 18,113 people
- Sponsor
- Takeda
Essential Hypertension
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
- Trial name
- NCT05359068
- Testing
- SPH3127 tablet, Valsartan
- Where
- 40 sites in China
- Volunteers
- 957 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Primary Hypertension
Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension
The purpose of this study is to assess the safety and efficacy of renal denervation with sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension in China.
- Trial name
- NCT03511313
- Testing
- Renal denervation, Renal angiography
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Synaptic Medical Corporation
Hypertension
An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])
Antihypertensive drugs aim to reduce blood pressure (BP) either through decrease of the total peripheral resistance through vasodilatation at the level of arterioles (microcirculation) or by decreasing the cardiac output through…
- Trial name
- NCT01079962
- Testing
- Bisoprolol, Atenolol
- Where
- South Korea
- Volunteers
- 209 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
Glaucoma, Ocular Hypertension
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT00061503
- Testing
- Travoprost
- Where
- United States
- Sponsor
- Alcon Research
Normal Tension Glaucoma (NTG)
A Study to Evaluate Safety and Tolerability of QLS-101 in NTG
A randomized active-controlled multi-site double-masked 28 day study to evaluate the safety and tolerability of QLS-101 versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with normal tension…
- Trial name
- NCT04857827
- Testing
- QLS-101, Timolol maleate PF 0.5% ophthalmic solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Qlaris Bio, Inc.
Overweight and Obesity
Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
To determine the efficacy of Palatinose versus sucrose on Flow Mediated Dilation (FMD) in healthy subjects with mild hypertension.
- Trial name
- NCT03986775
- Testing
- isomaltulose, sucrose
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605
A phase 3 study to evaluate efficacy and safety of HCP1401
- Trial name
- NCT02916602
- Testing
- HCP1401, HCP0605
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension
Hypertension is one of the most important preventable contributors to disease and death in the United States and represents the most common condition seen in the primary care setting.
- Trial name
- PGEN for HTN (NCT02988245)
- Testing
- Geneticure Panel for HTN therapy, JNC-8
- Where
- 15 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Geneticure, LLC
Heart Failure With Preserved Ejection Fraction (HFpEF), Hypertension
Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System
This study is a prospective, double blind, self-controlled, randomized, cross-over study to evaluate the feasibility, efficacy, and safety of treating patients with Heart Failure with preserved Ejection Fraction (HFpEF)…
- Trial name
- RelieveHFpEFII (NCT06036186)
- Testing
- BaroPacing treatment, Standard treatment
- Where
- 3 sites in India
- Volunteers
- 16 people
- Sponsor
- BaroPace Inc.
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension.
- Trial name
- NCT00413413
- Testing
- Valsartan/amlodipine 80/5 mg, Valsartan 80 mg, Valsartan 160 mg
- Where
- 19 sites in China
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
STUDY OBJECTIVES Primary objective To evaluate the effect of macitentan 10 mg on pulmonary vascular resistance (PVR) as compared to placebo in subjects with pulmonary hypertension (PH) after left ventricular assist device (LVAD)…
- Trial name
- SOPRANO (NCT02554903)
- Testing
- Macitentan 10mg
- Where
- 50 sites in United States
- Volunteers
- 57 people
- Sponsor
- Actelion
Hypertension, Uncontrolled Hypertension
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
- Trial name
- NCT07090161
- Testing
- iloperidone
- Where
- 28 sites in United States
- Volunteers
- 240 people
- Sponsor
- Vanda Pharmaceuticals
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH
Hypertension
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.
- Trial name
- EASE (NCT00546754)
- Testing
- losartan potassium (+) hydrochlorothiazide, Comparator: Valsartan (+) Hydrochlorothiazide
- Volunteers
- 808 people
- Sponsor
- Organon and Co